Volume 19 Issue 10
Oct.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(10): 1658-1661,1728
LI Xi-mei, LIN Li, MAO Yu-lei, CHEN Xin-xiao, FENG Ze-jiao, LIAO Hai-hong. Effect of long chain noncoding RNA BCYRN1 on malignant biological behavior of SKOV3 cells[J]. Chinese Journal of General Practice, 2021, 19(10): 1658-1661,1728. doi: 10.16766/j.cnki.issn.1674-4152.002135
Citation: LI Xi-mei, LIN Li, MAO Yu-lei, CHEN Xin-xiao, FENG Ze-jiao, LIAO Hai-hong. Effect of long chain noncoding RNA BCYRN1 on malignant biological behavior of SKOV3 cells[J]. Chinese Journal of General Practice, 2021, 19(10): 1658-1661,1728. doi: 10.16766/j.cnki.issn.1674-4152.002135
shu

Effect of long chain noncoding RNA BCYRN1 on malignant biological behavior of SKOV3 cells

doi: 10.16766/j.cnki.issn.1674-4152.002135
  • 1.

    Department of Obstetrics and Gynecology, Wenzhou Central Hospital, Wenzhou, Zhejiang 325000, China

Funds:

 2019RC285

  • Received Date: 2020-12-12
    Available Online: 2022-02-15
    Abstract
  •   Objective  To investigate the expression of long chain non-coding RNA brain cytoplasmic RNA-1 (BCYRN1) in ovarian cancer and its effect on the malignant biological behaviour of SKOV3 cells.  Methods  A total of 32 ovarian cancer tissues and their corresponding adjacent tissues treated in Wenzhou Central Hospital from March 2017 to March 2019 were selected. Normal ovarian epithelial cell lines (IOSE) and ovarian cancer cell lines (SKOV3, HO8910, A2780) were purchased from ATCC. The level of BCYRN1 was detected by real-time PCR. SKOV3 cells were transfected with BCYRN1 high-expression plasmid and low-expression plasmid and their corresponding control substances, and cell lines with high and low expression of BCYRN1 were constructed. BrdU assay was used to detect cell proliferation, scratch healing test was used to detect cell migration, and Transwell assay was used to detect cell invasion.  Results  The expression of BCYRN1 in ovarian cancer tissues (5.64±1.02) was higher than that in adjacent tissues (2.12±0.65), and the levels of BCYRN1 in SKOV3, HO8910 and A27809 cells were (2.25±0.78), (2.85±0.78) and (3.12±1.01), respectively, which were significantly higher than those of IOSE (1.01±0.12). The high expression of BCYRN1 promoted the proliferation, migration and invasion of SKOV3 cells.  Conclusion  The expression of BCYRN1 is up-regulated in ovarian cancer, and it can be used as an oncogene to promote the progression of ovarian cancer.

     

    • FullText(HTML)
  • loading
    • References(32)
  • [1]
    YOKOI A, MATSUZAKI J, YAMAMOTO Y, et al. Integrated extracellular microRNA profiling for ovarian cancer screening[J]. Nat Commun, 2018, 9(1): 4319. doi: 10.1038/s41467-018-06434-4
    [2]
    MURALI R, GRISHAM R N, SOSLOW R A. The roles of pathology in targeted therapy of women with gynecologic cancers[J]. Gynecol Oncol, 2018, 148(1): 213-221. doi: 10.1016/j.ygyno.2017.11.020
    [3]
    SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67: 7-30. doi: 10.3322/caac.21387
    [4]
    HOSKINS P J, GOTLIEB W H. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature[J]. CA Cancer J Clin, 2017, 67: 493-506. doi: 10.3322/caac.21408
    [5]
    MOUFARRIJ S, DANDAPANI M, ARTHOFER E, et al. Epigenetic therapy for ovarian cancer: Promise and progress[J]. Clin Epigenetics, 2019, 11(1): 7. doi: 10.1186/s13148-018-0602-0
    [6]
    LI W, MA S, BAI X, et al. Long noncoding RNA WDFY3-AS2 suppresses tumor progression by acting as a competing endogenous RNA of microRNA-18a in ovarian cancer[J]. J Cell Physiol, 2019, 235(2): 1141-1154. doi: 10.1002/jcp.29028
    [7]
    KUMAR M M, GOYAL R. LncRNA as a therapeutic target for angiogenesis[J]. Curr Top Med Chem, 2017, 17(15): 1750-1757. doi: 10.2174/1568026617666161116144744
    [8]
    WANG H, FU Z, DAI C, et al. LncRNAs expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer[J]. Sci Rep, 2016, 6(10): 38983. DOI: 10.1038/srep38983.
    [9]
    YU W, XIANG D, JIA H, et al. The lncRNA BCYRN1 Functions as an Oncogene in Human Glioma by Downregulating miR-125a-5p in vitro[J]. Cancer Manag Res, 2020, 12(4): 1151-1161. http://www.researchgate.net/publication/339220153_The_lncRNA_BCYRN1_Functions_as_an_Oncogene_in_Human_Glioma_by_Downregulating_miR-125a-5p_in_vitro
    [10]
    DING S, JIN Y, HAO Q, et al. LncRNA BCYRN1/miR-490-3p/POU3F2, served as a ceRNA network, is connected with worse survival rate of hepatocellular carcinoma patients and promotes tumor cell growth and metastasis[J]. Cancer Cell Int, 2020, 20(3): 6. doi: 10.1186/s12935-019-1081-x
    [11]
    YU J H, CHEN Y. Clinical significance of lncRNA BCYRN1 in colorectal cancer and its role in cell metastasis[J]. Eur Rev Med Pharmacol Sci, 2019, 23(21): 9371-9378. http://www.ncbi.nlm.nih.gov/pubmed/31773686
    [12]
    ZHAI H, LI Y. BCYRN1 is correlated with progression and prognosis in gastric cancer[J]. Biosci Rep, 2019, 39(11): BSR20190505. DOI: 10.1042/BSR20190505.
    [13]
    KOSSA M, LEARY A, SCOAZEC J Y, et al. Ovarian cancer: A heterogeneous disease[J]. Pathobiology, 2018, 85(1-2): 41-49. doi: 10.1159/000479006
    [14]
    ZHANG Y, LI Y, WANG Q, et al. Identification of an lncRNA miRNA mRNA interaction mechanism in breast cancer based on bioinformatic analysis[J]. Mol Med Rep, 2017, 16(4): 5113-5120. doi: 10.3892/mmr.2017.7304
    [15]
    WANG J C, SU Z L, LU S N, et al. LncRNA HOXA-AS2 and its molecular mechanisms in human cancer[J]. Clin Chim Acta. 2018, 485(4): 229-233. http://www.onacademic.com/detail/journal_1000040413707910_6b87.html
    [16]
    SHI X Y, SUN Y Z, LI M, et al. LncRNA CADM1-AS1 serves as a new prognostic biomarker for gastric cancer[J]. Eur Rev Med Pharmacol Sci, 2019, 23(3): 232-238. http://www.ncbi.nlm.nih.gov/pubmed/31389606
    [17]
    TANG J, YAN T, BAO Y, et al. LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc[J]. Nat Commun, 2019, 10(1): 3499. doi: 10.1038/s41467-019-11447-8
    [18]
    QIU X, DONG J, ZHAO Z, et al. LncRNA LINC00668 promotes the progression of breast cancer by inhibiting apoptosis and accelerating cell cycle[J]. Onco Targets Ther, 2019, 12(43): 5615-5625. http://www.ncbi.nlm.nih.gov/pubmed/31371999
    [19]
    DU W L, FENG Z J, SUN Q Q. LncRNA LINC00319 accelerates ovarian cancer progression through miR-423-5p/NACC1 pathway[J]. Biochem Biophys Res Commun, 2018, 507(1-4): 198-202. doi: 10.1016/j.bbrc.2018.11.006
    [20]
    LONG X, SONG K, HU H, et al. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis[J]. J Exp Clin Cancer Res, 2019, 38(1): 345. doi: 10.1186/s13046-019-1329-2
    [21]
    ZHUANG X H, LIU Y, LI J L. Overexpression of long noncoding RNA HOXB-AS3 indicates an unfavorable prognosis and promotes tumorigenesis in epithelial ovarian cancer via Wnt/beta-catenin signaling pathway[J]. Biosci Rep, 2019, 39(8): BSR20190906. DOI: 10.1042/BSR20190906.
    [22]
    WU Y, YU D, JUN Z, et al. Long noncoding RNA NEAT1, regulated by LIN28B, promotes cell proliferation and migration through sponging miR-506 in high-grade serous ovarian cancer[J]. Cell Death Dis, 2018, 9(9): 861. doi: 10.1038/s41419-018-0908-z
    [23]
    LIANG H, YU T, HAN Y, et al. LncRNA PTAR promotes EMT and invasion‐metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression[J]. Mol Cancer, 2018, 17(1): 119. doi: 10.1186/s12943-018-0870-5
    [24]
    SOSINSKA P, MIKULA-PIETRASIK J, KSIAZEK K. The double-edged sword of long non-coding RNA: The role of human brain-specific BC200 RNA in translational control, neurodegenerative diseases, and cancer[J]. Mutat Res Rev Mutat Res, 2015, 766(10): 58-67. http://www.sciencedirect.com/science/article/pii/S1383574215000630
    [25]
    HU T, LU Y R. BCYRN1, a c-MYC-activated long non-coding RNA, regulates cell metastasis of non-small-cell lung cancer[J]. Cancer Cell Int, 2015, 15(2): 36. http://pdfs.semanticscholar.org/e3bf/2c072420f190019edae9c9fa7354af62198f.pdf
    [26]
    WANG Y, BAI W, WANG M, et al. Long non-coding RNA brain cytoplasmic RNA 1 acts as an oncogene and regulates cell proliferation and metastasis in non-small cell lung cancer[J]. J Nanosci Nanotechnol, 2019, 19(4): 1978-1985. doi: 10.1166/jnn.2019.16402
    [27]
    IACOANGELI A, ADZOVIC L, CHEN E Q, et al. Regulatory BC200 RNA in peripheral blood of patients with invasive breast cancer[J]. J Investig Med, 2018, 66(7): 1055-1063. doi: 10.1136/jim-2018-000717
    [28]
    IACOANGELI A, LIN Y, MORLEY E J, et al. BC200 RNA in invasive and preinvasive breast cancer[J]. Carcinogenesis, 2005, 25(2): 2125-2133.
    [29]
    ZHAO R H, ZHU C H, LI X K, et al. BC200 LncRNA a potential predictive marker of poor prognosis in esophageal squamous cell carcinoma patients[J]. Onco Targets Ther, 2016, 9(8): 2221-2226. http://pdfs.semanticscholar.org/192e/eb5d23eec52f6c25fdd7c3751103aff78635.pdf
    [30]
    GU L, LU L, ZHOU D, et al. Long noncoding RNA BCYRN1 promotes the proliferation of colorectal cancer cells via up-regulating NPR3 expression[J]. Cell Physiol Biochem, 2018, 48(10): 2337-2349. http://www.karger.com/Article/Pdf/492649
    [31]
    PENG J, HOU F, FENG J, et al. Long non-coding RNA BCYRN1 promotes the proliferation and metastasis of cervical cancer via targeting microRNA-138 in vitro and in vivo[J]. Oncol Lett, 2018, 15(1): 5809-5818. http://www.onacademic.com/detail/journal_1000040283511910_455c.html
    [32]
    KRAUS T F, GREINER A, GUIBOURT V, et al. Identification of stably expressed lncRNAs as valid endogenous controls for profiling of human glioma[J]. J Cancer, 2015, 6(1): 111-119. http://europepmc.org/articles/PMC4280393/pdf/jcav06p0111.pdf
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (131) PDF downloads(1) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return